What is the clinical significance of left ventricular dyssynchrony in the setting of left ventricular hypertrophy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clinical Significance of LV Dyssynchrony with Ventricular Hypertrophy

Left ventricular dyssynchrony in the setting of LV hypertrophy is clinically significant as it independently predicts adverse cardiovascular outcomes including mortality, heart failure progression, and hospitalizations, with the combination of dyssynchrony and hypertrophy conferring synergistically worse prognosis than either condition alone.

Prognostic Impact

LV dyssynchrony combined with hypertrophy creates a particularly high-risk phenotype through multiple mechanisms:

  • Mortality and Morbidity: Ventricular dyssynchrony has been directly associated with increased mortality in heart failure patients 1, 2, 3, 2. When combined with LV hypertrophy, this risk amplifies synergistically 4.

  • Mechanical Consequences: The dyssynchronous contraction pattern causes:

    • Suboptimal ventricular filling
    • Reduced LV dP/dt (contractile force)
    • Prolonged and more severe mitral regurgitation
    • Paradoxical septal wall motion 1, 2, 1, 2

Context-Specific Significance

In Hypertrophic Cardiomyopathy (HCM)

Dyssynchrony in HCM patients carries distinct prognostic weight:

  • Low-Risk HCM Patients: Even in patients with HCM risk-SCD scores <6%, mechanical dyssynchrony parameters (phase SD and phase histogram bandwidth) independently predict major adverse cardiovascular events including mortality, heart failure rehospitalization, stroke, and syncope 5.

  • Prevalence: Mechanical dyssynchrony is common in HCM, particularly in apical forms, and occurs alongside diastolic dysfunction 6.

In Hypertensive Heart Disease

The progression from hypertension to LV hypertrophy to dyssynchrony represents a critical pathophysiologic cascade:

  • Frequency: Dyssynchrony occurs in 40.5% of hypertensive patients versus 19.5% of normotensive controls 7.

  • Correlation with Hypertrophy Grade: There is a moderate-to-strong correlation between severity of LV hypertrophy and degree of dyssynchrony, with 75% of patients with moderate hypertrophy demonstrating dyssynchrony compared to only 20% without hypertrophy 7.

  • Progression Marker: Diastolic dysfunction and dyssynchrony associated with LV hypertrophy predict disease progression in hypertensive patients with comorbidities like diabetes and obesity 8.

In Systolic Heart Failure

The combination of LV hypertrophy and dyssynchrony in heart failure patients represents the highest-risk subgroup 4:

  • Patients with both phase SD >37° and LV mass index >122.7 g/m² had the highest cardiac event rates
  • Both parameters were independent predictors with hazard ratios of 1.038 for phase SD and 1.005 for LVMI
  • The combination provided incremental prognostic value beyond age, NYHA class, eGFR, and BNP

Therapeutic Implications

Cardiac Resynchronization Therapy (CRT)

For patients meeting specific criteria, CRT addresses dyssynchrony with proven mortality benefit:

Class I Indications (strongest evidence) 9, 10, 11:

  • LVEF ≤35%
  • Sinus rhythm
  • NYHA class II-IV symptoms on optimal medical therapy
  • QRS duration ≥150 ms with LBBB pattern

Outcomes: CRT reduces:

  • All-cause mortality by 25-36% 1, 2, 3, 1, 2
  • Heart failure hospitalizations by 32-52% 1, 2, 1
  • Combined hospitalization and mortality risk by 20-37% 2, 10, 11

Important Caveats

CRT is NOT indicated 12:

  • In patients with narrow QRS (<130 ms), where it may cause harm 12
  • In obstructive HCM specifically for dyssynchrony (distinct from systolic heart failure) 13, 14, 15

Atrial Fibrillation: In AF patients, CRT benefit requires achieving >95-98% biventricular pacing, often necessitating AV nodal ablation 12.

Clinical Assessment Strategy

  1. Identify LV hypertrophy via echocardiography or CMR
  2. Assess for dyssynchrony using:
    • QRS duration and morphology (ECG)
    • Tissue Doppler imaging parameters
    • Phase analysis on gated SPECT MPI (phase SD, phase histogram bandwidth)
  3. Evaluate functional status: NYHA class, exercise capacity, symptoms
  4. Risk stratify based on combined presence of hypertrophy severity and dyssynchrony degree
  5. Consider CRT if meeting guideline criteria for systolic heart failure with dyssynchrony

Key Pitfalls to Avoid

  • Do not rely solely on QRS duration: Echocardiographic dyssynchrony measures provide additional prognostic information, particularly in HCM and hypertensive heart disease where QRS may be normal 5, 6, 7.

  • Do not assume all dyssynchrony is treatable with CRT: The evidence for CRT is specific to systolic heart failure with reduced ejection fraction and wide QRS, not preserved EF or HCM 13, 14, 15.

  • Recognize the synergistic risk: The combination of hypertrophy and dyssynchrony is worse than either alone, requiring more aggressive risk factor modification and closer monitoring 4, 8.

The clinical significance lies in recognizing this combination as a high-risk phenotype requiring intensive management, appropriate risk stratification, and consideration of device therapy when guideline criteria are met.

References

Related Questions

How can I explain mild concentric hypertrophy and grade 1 diastolic dysfunction to a patient?
Should a patient with mild concentric left ventricular hypertrophy on echocardiography be referred to a cardiologist?
What is the clinical significance of sinus tachycardia with a 41 bpm increase in ventricular rate, minimal voltage criteria for left ventricular hypertrophy (R wave in aVL), and nonspecific ST‑ and T‑wave abnormalities that have changed from inverted T waves in the inferior leads to less prominent T‑wave inversion in the lateral leads compared with the prior electrocardiogram?
What studies are warranted in a teenager with newly diagnosed concentric Left Ventricular (LV) hypertrophy consistent with Hypertrophic Cardiomyopathy (HCM)?
What postnatal complications are likely and what preparations are needed for a 24‑year‑old gravida 1 woman at 37 weeks + 2 days gestation with suspected ductus arteriosus constriction or coarctation of the aorta, who has a history of hydrocephalus treated with a ventriculoperitoneal shunt?
Is work clearance appropriate for a patient with fatty liver disease who has normal alanine aminotransferase (ALT) levels and a Fibroscan indicating no significant fibrosis?
In a patient with ferritin less than 45 µg/L but normal hemoglobin, should a gastrointestinal referral be made?
Which laboratory tests should be drawn in the hospital for a patient receiving emicizumab (Hemlibra)?
In a 17-year-old male with hypercalcemia (serum calcium 10.8 mg/dL), how should the condition be investigated?
What is the appropriate management for a patient with hypertension and a normal ejection fraction incidentally discovered on a routine two‑dimensional echocardiogram?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.